Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pathologic Complete Response 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Colonic Polyps 1 Adenomatous Polyposis Coli 1

Interventions

Cisplatin 9 pembrolizumab 7 Radiosurgery 6 Gemcitabine 6 Paclitaxel 5 Dexamethasone 5 Taxes 4 Carboplatin 4 trametinib 3 ibrutinib 3 Surveys and Questionnaires 3 Standard of Care 3 Radiotherapy 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Lenalidomide 3 Fluorouracil 3 Erlotinib Hydrochloride 3 Blood Specimen Collection 3 Ascorbic Acid 3 venetoclax 2 veliparib 2 tocilizumab 2 pazopanib 2 obinutuzumab 2 naquotinib 2 lenvatinib 2 fludarabine 2 enzalutamide 2 Vemurafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasms × Sulindac × Clear all

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡